Sentinel node mapping for melanoma: results of trials and current applications.
The value of sentinel node (SN) biopsy as a staging procedure and as a guide to prognosis with patients who have melanoma is now clearly established. As well, there is recent clinical trial evidence suggesting a survival benefit for patients found to be SN positive who have an immediate complete lymph node dissection (CLND), compared with those with nodal disease not treated by CLND until it becomes clinically apparent. Clinical trials are ongoing to determine whether CLND is necessary in all patients who are found to be SN positive.
Thompson
John F
JF
Discipline of Surgery, The University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown NSW 2050, Sydney, Australia. john.thompson@smu.org.au
Shaw
Helen M
HM
D000367:Age Factors; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D016019:Survival Analysis
D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2